HWM
RPRX icon

HB Wealth Management’s Royalty Pharma RPRX Stock Holding History

HB Wealth Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13M Buy
20,240
+2,011
+11% +$105K 0.01% 690
2026
Q1 		$874K Buy
18,229
+3,488
+24% +$153K 0.01% 718
2025
Q4 		$570K Buy
14,741
+1,008
+7% +$38.4K ﹤0.01% 853
2025
Q3 		$485K Buy
13,733
+1,190
+9% +$43.1K ﹤0.01% 872
2025
Q2 		$452K Sell
12,543
-65
-0.5% -$2.15K ﹤0.01% 783
2025
Q1 		$392K Buy
+12,608
New +$400K ﹤0.01% 853

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HB Wealth Management's RPRX Position: Q2 2026 in Review

HB Wealth Management increased its Royalty Pharma (RPRX) stake by 11% in Q2 2026, buying an estimated $105K and bringing the position to 20,240 shares worth $1.13M. The position accounts for 0.01% of the portfolio, ranked #690.

HB Wealth Management first reported a position in RPRX in Q1 2025 and has held it in 6 quarters since. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • HB Wealth Management held 20,240 shares of Royalty Pharma worth $1.13M as of Q2 2026.
  • HB Wealth Management bought 2,011 Royalty Pharma shares in Q2 2026, an estimated $105K.
  • Royalty Pharma made up 0.01% of HB Wealth Management's portfolio in Q2 2026, its #690 holding.
  • HB Wealth Management first reported a position in Royalty Pharma in Q1 2025 and has held it in 6 quarters since.
  • 641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on HB Wealth Management's 13F filing for Q2 2026, filed 29 Jul 2026.